The integration of genomics testing and functional proteomics in the era of personalized medicine

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench

(2017) Kenichi Suda et al.   Journal of Thoracic Oncology

Lung cancer: current therapies and new targeted treatments

(2017) Fred R Hirsch et al.   LANCET

Combined inhibition of β-catenin and Bcr–Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo

(2017) H Zhou et al.   LEUKEMIA

The evolving genomic landscape of urothelial carcinoma

(2017) Alexander P. Glaser et al.   Nature Reviews Urology

A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer

(2017) Michael Michael et al.   Targeted Oncology

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

(2017) Christophe Massard et al.   Cancer Discovery

Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases

(2017) Stephanie U. Greer et al.   Genome Medicine

Targeting Fibroblast Growth Factor Receptor 1 for Treatment of Soft-Tissue Sarcoma

(2016) Priya Chudasama et al.   CLINICAL CANCER RESEARCH

First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

(2016) R. Kim et al.   EUROPEAN JOURNAL OF CANCER

Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives

(2016) Li Zhou et al.   Expert Review of Proteomics

Clinical implications of recent advances in proteogenomics

(2016) Marie Locard-Paulet et al.   Expert Review of Proteomics

Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine

(2016) Devon M. Cayer et al.   HUMAN MOLECULAR GENETICS

FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)

(2016) MASARU KATOH   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Proteogenomics connects somatic mutations to signalling in breast cancer

(2016) Philipp Mertins et al.   NATURE

Precision medicine in cardiology

(2016) Elliott M. Antman et al.   Nature Reviews Cardiology

Limits to Personalized Cancer Medicine

(2016) Ian F. Tannock et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutics Targeting FGF Signaling Network in Human Diseases

(2016) Masaru Katoh   TRENDS IN PHARMACOLOGICAL SCIENCES

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

(2016) A. Pearson et al.   Cancer Discovery

Development and clinical application of an integrative genomic approach to personalized cancer therapy

(2016) Andrew V. Uzilov et al.   Genome Medicine

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

(2016) Terence G. Hall et al.   PLoS One

Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes

(2015) Marta Pelay-Gimeno et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

(2015) Fabrice André et al.   BREAST CANCER RESEARCH AND TREATMENT

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing

(2015) T. Helsten et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

(2015) Josep Tabernero et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells

(2015) Y. Kwak et al.   MOLECULAR CANCER THERAPEUTICS

A New Initiative on Precision Medicine

(2015) Francis S. Collins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

(2015) Daniela Sia et al.   Nature Communications

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

(2015) M. Hagel et al.   Cancer Discovery

Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors

(2015) Daniel H. Hovelson et al.   NEOPLASIA

Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer

(2015) Jinjia Chang et al.   Oncotarget

Acquired resistance to TKIs in solid tumours: learning from lung cancer

(2014) D. Ross Camidge et al.   Nature Reviews Clinical Oncology

Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells

(2014) J Wang et al.   ONCOGENE

What is personalized medicine: sharpening a vague term based on a systematic literature review

(2013) Sebastian Schleidgen et al.   BMC Medical Ethics

FGFR2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD4547

(2013) L. Xie et al.   CLINICAL CANCER RESEARCH

FGF Receptors: Cancer Biology and Therapeutics

(2013) Masaru Katoh et al.   MEDICINAL RESEARCH REVIEWS

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

(2013) Garrett M Frampton et al.   NATURE BIOTECHNOLOGY

A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets

(2012) Niantao Deng et al.   GUT

Targeted Disruption of the BCL9/ -Catenin Complex Inhibits Oncogenic Wnt Signaling

(2012) K. Takada et al.   Science Translational Medicine

ALKoma: A Cancer Subtype with a Shared Target

(2012) Hiroyuki Mano   Cancer Discovery